...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Expectations for the AGM?
Reply New Message
Prev Message Back To Forum Threaded View Next Message

"The Royalty shares in my opinion would have to be excluded to make RVX saleable."

They can't just exclude them without compensation to Zenith. Perhaps a negotiated cash payment to remove them.  RVX just sells for less than it would if there were no royalty shares.

 

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply